What is Vor Biopharma's D&A?

Vor Biopharma (VOR) reported D&A of $28K in Q1 2026.

How has Vor Biopharma's D&A changed year-over-year?

Vor Biopharma's D&A decreased by 96.6% year-over-year, from $825K to $28K.

What is the long-term trend for Vor Biopharma's D&A?

Over 4 years (2021 to 2025), Vor Biopharma's D&A has grown at a 20.4% compound annual growth rate (CAGR), from $1.41M to $2.95M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Vor Biopharma VOR D&A

D&A at other companies

Johnson & JohnsonJNJ

$2B+13.1%

AmgenAMGN

$1.12B-19.5%

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Dianthus TherapeuticsDNTH

$32K+18.5%

Cullinan Therapeutics, Inc.CGEM

$79K+3.9%

Design Therapeutics, Inc.DSGN

$157K-1.3%

Other financials

Income statement

See full

Operating income-$35.2M-5.6%

Net income-$219.6M-576%

EPS (diluted)-$5.11+1.9%

Balance sheet

See full

Cash & equivalents$169.9M+239%

Total debt$2.9M-90.5%

Total equity-$150.4M-328%

Total assets$506.7M+364%

Cash flow

See full

Operating cash flow-$38.2M-23.1%

CapEx$48.0K-79.2%

Free cash flow-$38.3M-22.4%

Valuation

See full

Market cap$784.61M+2,513%

Enterprise value$617.68M+5,639%

Returns & leverage

See full

Return on equity-125.4%+671pp

Debt / equity0.5×+0.2×

Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vor Biopharma's D&A?: Vor Biopharma (VOR) reported D&A of $28K in Q1 2026.
How has Vor Biopharma's D&A changed year-over-year?: Vor Biopharma's D&A decreased by 96.6% year-over-year, from $825K to $28K.
What is the long-term trend for Vor Biopharma's D&A?: Over 4 years (2021 to 2025), Vor Biopharma's D&A has grown at a 20.4% compound annual growth rate (CAGR), from $1.41M to $2.95M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.